Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.

Literature DB >> 15714263

The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.

Abstract

We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Under conservative assumptions, our estimates imply that the average annual increase in life expectancy of the entire population resulting from new drug launches is about one week, and that the incremental cost effectiveness ratio (new drug expenditure per person per year divided by the increase in life-years per person per year attributable to new drug launches) is about $6750--far lower than most estimates of the value of a statistical life-year.

Entities: Species

Mesh：

Substances：

Year: 2005 PMID： 15714263 DOI： 10.1007/s10754-005-6601-7

Source DB: PubMed Journal: Int J Health Care Finance Econ ISSN： 1389-6563

6 in total

1. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS.

Authors: F R Lichtenberg
Journal: Health Aff (Millwood) Date: 2001 Sep-Oct Impact factor: 6.301

2. Is technological change in medicine worth it?

Authors: D M Cutler; M McClellan
Journal: Health Aff (Millwood) Date: 2001 Sep-Oct Impact factor: 6.301

3. Do (more and better) drugs keep people out of hospitals?

Authors: F R Lichtenberg
Journal: Am Econ Rev Date: 1996-05

4. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.

Authors: Patricia M Danzon; Y Richard Wang; Liang Wang
Journal: Health Econ Date: 2005-03 Impact factor: 3.046

5. Early statin treatment following acute myocardial infarction and 1-year survival.

Authors: U Stenestrand; L Wallentin
Journal: JAMA Date: 2001 Jan 24-31 Impact factor: 56.272

6. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Authors: Holcombe E Grier; Mark D Krailo; Nancy J Tarbell; Michael P Link; Christopher J H Fryer; Douglas J Pritchard; Mark C Gebhardt; Paul S Dickman; Elizabeth J Perlman; Paul A Meyers; Sarah S Donaldson; Sheila Moore; Aaron R Rausen; Teresa J Vietti; James S Miser
Journal: N Engl J Med Date: 2003-02-20 Impact factor: 91.245

6 in total

25 in total

Review 1. Diagnosing the decline in pharmaceutical R&D efficiency.

Authors: Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal: Nat Rev Drug Discov Date: 2012-03-01 Impact factor: 84.694

2. Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan.

Authors: Chee-Ruey Hsieh; Ya-Ming Liu; Chia-Lin Chang
Journal: Eur J Health Econ Date: 2011-12-27

The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001.

1. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS.

2. Is technological change in medicine worth it?

3. Do (more and better) drugs keep people out of hospitals?

4. The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s.

5. Early statin treatment following acute myocardial infarction and 1-year survival.

6. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Review 1. Diagnosing the decline in pharmaceutical R&D efficiency.

2. Endogenous technological change in medicine and its impact on healthcare costs: evidence from the pharmaceutical market in Taiwan.

3. Comparative effectiveness regulations and pharmaceutical innovation.

Review 4. How to improve R&D productivity: the pharmaceutical industry's grand challenge.

5. Price differentiation and transparency in the global pharmaceutical marketplace.

6. Medicine, ageing and human longevity. The economics and ethics of anti-ageing interventions.

7. Should we really worry about "launch delays" of new drugs in OECD countries?

8. The impact of new drug launches on the loss of labor from disease and injury: evidence from German panel data.

9. Does Medical Expansion Improve Population Health?

10. Forecasting drug utilization and expenditure in a metropolitan health region.